

CURRICULUM VITA

Marcus Milton Reidenberg



CURRENT POSITIONS

Cornell University Medical College
New York, NY

Professor of Pharmacology
Professor Public Health
Professor of Medicine and Head,
Division of Clinical Pharmacology
Assistant Dean, Departmental
Associates Program

PREVIOUS POSITIONS

Cornell University Medical College
New York, New York

1981-1982, Acting Associate Dean

1976-1980, Professor of
Pharmacology/Associate Professor
of Medicine, and Head,
Division of Clinical Pharmacology

The New York Hospital
New York, New York

1975-1980, Associate Attending
Physician, 1980-2006 Attending
Physician

Rockefeller University
New York, New York

1975-1977, Visiting Associate
Physician
1977-1999, Visiting Physician

Cornell University Medical College
New York, New York

1975-1976, Associate Professor of
Pharmacology/Associate Professor
of Medicine

Temple University
Philadelphia, Pennsylvania

1972-1974, Associate Professor of
Pharmacology/Associate Professor
of Medicine and Head, Section of
Clinical Pharmacology

Temple University
Philadelphia, Pennsylvania

1971-1972, Associate Professor of
Pharmacology/Assistant Professor
of Medicine and Head, Section of
Clinical Pharmacology

Department of Biochemistry
St. Mary's Hospital Medical School
London, England

1969-1970, Visiting Scientist with
Professor [REDACTED] (b) (6)

Department of Clinical Pharmacology
Karolinska Institutet
Stockholm, Sweden

1970, Visiting Scientist with
Professor [REDACTED] (b) (6)

Temple University
Philadelphia, Pennsylvania

1967-1971, Assistant Professor of
of Pharmacology and Internal
Medicine

1965-1967, Assistant Professor of
Pharmacology, Instructor of
Internal Medicine

1965, Instructor of Pharmacology,
Instructor of Internal Medicine

1962-1965, Instructor of
Pharmacology, Resident in Internal
Medicine

U.S. Navy

1960-1962, Senior Medical Officer
U.S. Naval Station, Trinidad

Temple University
Philadelphia, Pennsylvania

1959-1960, U.S.P.H.S.
Postdoctoral Fellowship in
Pharmacology with Dr. [REDACTED] (b) (6)

Community General Hospital
Reading Pennsylvania

1958-1959, Internship

Temple University
Philadelphia, Pennsylvania

1955-1958, Summer Student Research
Fellow in Physiology and
Pharmacology with Drs. (b) (6)
and (b) (6)

1954-1958, Medical School
(M.D., 1958)

Cornell University
Ithaca, New York

1951-1954, Pre-medical (no degree)

SOCIETY MEMBERSHIP

Association of American Physicians

Sigma Xi

American Society for Clinical
Investigation

The Harvey Society

American College of Physicians
(Fellow)

The New York Academy of Sciences

Society for Experimental Biology
and Medicine

American Society for Pharmacology
and Experimental Therapeutics (1967)

American Association for the
Advancement of Science

American Society of Tropical
Medicine and Hygiene

Royal Society of Tropical Medicine
and Hygiene

American Society for Clinical
Pharmacology and Therapeutics

American Federation for Clinical
Research

Royal Society of Medicine (Fellow)

International Association for
the Study of Pain

American Geriatrics Society

LICENSES AND CERTIFICATIONS AND AWARDS

License to Practice Medicine in Pennsylvania and New York.

Certified by American Board of Internal Medicine, December 7, 1967.

Fred Conrad Koch Travel Fellow of The Endocrine Society Award, 1968.

Research Career Development Award, National Institute of General Medical Sciences, National Institutes of Health, 1970-1974.

Temple University S.A.M.A. Teacher Recognition ("Golden Apple") Award, 1973.

Rawls-Palmer Award of the American Society for Clinical Pharmacology and Therapeutics, 1981.

Experimental Therapeutics Award of the American Society for Pharmacology and Experimental Therapeutics, 1983.

William Creasy Visiting Professor of Clinical Pharmacology at the University of Oregon Medical School, 1981; University of Cincinnati Medical School, 1984.

Julius W. Sturmer Memorial Lecture Award of the Philadelphia College of Pharmacy and Science, 1982.

Cornell University Medical College Second Year Teaching Award, 1986, 1992.

Temple University Medical School Alumni Achievement Award, 1988.

Cornell University Medical College Alumni Association Honorary Fellowship, 1993.

The Departmental Associates of The New York Hospital-Cornell Medical Center established a program to provide minority college students with summer research opportunities and named it the Marcus M. Reidenberg Gateways to Science Program, 1993

Pfizer Visiting Professor of Clinical Pharmacology, Meharry Medical College, 1995

Fellow, American Association for the Advancement of Science, 1995

Cornell University Medical College Senior list teaching award, 1995, 1999, 2001

Henry B. Elliott Award for Distinguished Service of the American Society for Clinical Pharmacology and Therapeutics, 1999.

Harry Gold Award for Research and Teaching Excellence in Clinical Pharmacology of the American Society for Pharmacology and Experimental Therapeutics, 1999.

Elliot Hochstein Teaching Award of the Joan and Sanford Weill Medical College of Cornell University, 1999.

Nathaniel T. Kwit Memorial Distinguished Service Award, American College of Clinical Pharmacology, 1999.

Weill Medical College of Cornell University Award for Teaching Excellence, 2000.

Temple University Medical School 2001 Alumnus of the Year Award.

American Society for Clinical Pharmacology and Therapeutics Oscar B. Hunter Memorial Award in Therapeutics, 2008

Torald Sollmann Award of the American Society for Pharmacology and Experimental Therapeutics, 2011

EXTRACURRICULAR ACTIVITIES

World Health Organization

Expert Advisory Panel on Drug Evaluation, Member 1989-1993, 1993-1997, 1997-2001, 2001-2005, 2005-2009, 2009-2013

Expert Committee on the Use of Essential Drugs, Rapporteur, 1989

Temporary Advisor, WHO International Drug Monitoring Program, 1990

Expert Committee on the Use of Essential Drugs, Rapporteur, 1991

Expert Committee on the Use of Essential Drugs, Rapporteur, 1993

Temporary Advisor, Special Program of Research, Development, and Research Training in Human Reproduction, 1992

Advisor about Essential Drugs Program, Ministry of Health, People's Republic of China, 1993

Expert Committee on the Use of Essential Drugs, 1995, 2002

Expert Committee on the Use of Essential Drugs, Rapporteur, 1999

Plenary Lecturer, Silver Anniversary meeting of national Centers participating in WHO Programme for International Drug Monitoring, 2002

Expert Committee on the Selection and Use of Essential Medicines, Vice-Chairman, 2003, Vice-Chairman, 2005, Chairman, 2007, 2009

American College of Physicians

Chairman, Ad Hoc Committee on Clinical Pharmacology, 1971

Chairman, Committee on Clinical Pharmacology, 1972-1977

Member, MKSAP VI Committee, 1980-1982

Director, C.M.E. Course, Individualization of Drug Therapy, 1973
Director, C.M.E. Course, The Clinical Pharmacology of Symptom Control, 1982

American Society for Pharmacology and Experimental Therapeutics

Member of Executive Committee, Division of Clinical Pharmacology,
1971-1978, 1980-

Acting Chairman, Executive Committee, Division of Clinical Pharmacology,
1972

Membership Committee, 1979-1982; Chairman, 1981-1982

Educational Affairs Committee, Chairman of Subcommittee on Continuing
Medical Education, 1980-1981

Program Chairman for Second World Congress on Clinical Pharmacology,
Washington, D.C., July-August 1983

Nominating Committee, 1984

Member, Board of Publications Trustees, 1985- 2001

Member, Harry Gold Award Committee 2000-2001, Chair 2001-2004

International Union of Pharmacology

Member, Working Group on Drug Metabolism, 1982-1984

Vice Chairman, Section on Clinical Pharmacology, 1984-1987

Chairman, Section of Clinical Pharmacology, 1987-1989

Immediate Past Chairman, Section of Clinical Pharmacology, 1989-1992

Member, Working Group to Review IUPHAR Statutes, 1988

Auditor, 1990-1993

Member, International Advisory Committee, World Conference on Clinical
Pharmacology of 1992, 1996

Member, Membership Committee, 1990-1993, 1994-1997, 1997-2001

American Society for Clinical Pharmacology and Therapeutics

Board of Directors, 1975-1977, 1979-1982, 1986-2001

Vice President, 1982-1983

President Elect, 1983-1984

President, 1984-1985

Multiple Committee Memberships, 1980-2001

Consultant, South-to-South Cooperation in Reproductive Health, 1991-1999

Chairman, Session on Clinical Pharmacokinetics, Gordon Research Conference on
Drug Metabolism, 1971 and 1976

National Academy of Sciences

Consultant to Drug Research Board, 1968-1970

Speaker. I.O.M. Workshop on Pharmacokinetics and Drug Interactions in the

Elderly, 1997

Food and Drug Administration

Consultant, 1971

Member, Project Advisory Group, Experiment in Early Postmarketing Surveillance of Drugs, 1977-1982

Invited Expert, Fertility and Maternal Health Drugs Advisory Committee, 1990

Member, Over-The-Counter (OTC) Drugs Advisory Committee, 1992-1995, 2011-

Anesthetic and Life support Drugs Advisory Committee, Member 2001

Invited Participant, CPDD, FDA, DEA, NIH workshop on Abuse Liability Assessment of CNS Drugs, 2002.

Consultant, Walter Reed Army Medical Center, 1974-1977

National Institutes of Health

Special Study Section, 1980 and 1986

Task Force on Geriatric Medicine, 1980

Pharmacological Sciences Review Committee (Study Section), 1980-1985

Workshop Chairman, Program Initiatives in Gerontological Pharmacology 1981

Consensus Conference on Pain Management Panel Member, 1986

Epidemiology and Disease Control Special Study Section, 1990

Data Safety Monitoring Review Committee for MIRA trial, 1991-1993

Joint Commission on Prescription Drug Use, Member, 1976; Vice Chairman, 1977-1980

Consultant, Hoffmann-La Roche, Inc., 1975-

Advisory Board, Orphan Medical, 1994-2001

Consultant, Genta, Inc. 1994-1996

Consultant, Bristol Myers Squibb, 1995-2001

Consultant, Hoechst Marion Roussel, 1996-1998

Association of American Medical Colleges Ad Hoc Committee on AAMC/FDA Interactions, 1978-1982

Merck Company Foundation

International Clinical Pharmacology Fellowship Awards Selection Committee 1992-1995,

Chairman 1994-1996

American Federation for Aging Research

Research Committee 1986-1992
Fellowship Selection Committee 1993, 1994, 1995, 1997, 1998, 1999, 2000, 2001

Award Committee for Nellie Westerman Prize for Research in Ethics of the
American Federation for Clinical Research, 1975-1978

USP - Delegate from Cornell University Medical College, 1975-1980
Advisory Panel on Geriatrics, Committee on Revision, 1980-1990

Consultant, Office of Technology Assessment, Congress of the United States,
1981

Consultant, New York State Department of Health, 1988-1992

Vice Chairman, Greater Philadelphia Committee for Medical-Pharmaceutical
Sciences, 1968-1974

Representative of Pennsylvania Medical Society to Task Force on Drug Handling
of the Commonwealth of Pennsylvania, 1968

UNICEF

Emergency Operations in former Yugoslavia, Advisor for Manual for Essential Drugs, 1994

USP DI-AMA DE Advisory Council, 1995-1997

Médecins Sans Frontieres (Doctors Without Borders)

Participant in workshop, The Crisis of Neglected Diseases: Developing Treatments and
Ensuring Access, 2002

Organizer, Esteve Foundation Workshop on Peer Review of Scientific Publications, 2002

Alliance for a Stronger FDA 2008-

Member, Board of Directors, Aminopterin, LLC, 2010-

SCIENTIFIC PUBLICATIONS

Associate Editor, Clinical Pharmacology and Therapeutics, 1980-1984

Editor, Clinical Pharmacology and Therapeutics, 1985-2001

Editor, Emeritus, Clinical Pharmacology and Therapeutics, 2002-

EDITORIAL BOARDS

Primary Care, 1974-1979
Journal of Dialysis, 1976-1985
Clinical Pharmacokinetics, 1976-1997
Archives Internationales de Pharmacodynamie et de Therapie, 1976-1995
Pharmacology, 1978-1985
Clinical Pharmacology and Therapeutics, 1978-1980
Rational Drug Therapy, 1978-1985
Renal Physiology, 1978-1985
Therapeutic Drug Monitoring, 1978-2001
Trends in Pharmacological Sciences, 1978-2000
Clinical Nephrology, 1978-1995
CHAIN, 2009-2011
Journal of Pharmacology and Pharmacotherapeutics 2011-

BOOKS

Reidenberg, M.M.: Renal Function and Drug Action. Philadelphia, PA, W.B. Saunders Co., 1971.

Reidenberg, M.M., editor: Individualization of Drug Therapy. Medical Clinics of North America, Philadelphia, PA, W.B. Saunders Co., September, 1974.

Rubin, A.L., Stenzel, K.H., and Reidenberg, M.M., editors: Symposium on Drug Action and Metabolism in Renal Failure. Amer. J. Med., 62:459-563, 1977.

Reidenberg, M.M., editor: The Clinical Pharmacology of Symptom Control. Medical Clinics of North America, Philadelphia, PA, W.B. Saunders Co., September, 1982.

Lemberger, L. and Reidenberg, M.M., editors: Proceedings of Second World Conference on Clinical Pharmacology and Therapeutics. American Society for Pharmacology and Therapeutics, Bethesda, MD, 1984.

Reidenberg, M.M. and Erill, S., editors: Drug-Protein Binding. Praeger, New York, NY, 1986.

Reidenberg, M.M., editor: The Clinical Pharmacology of Biotechnology Products. Excerpta Medica, New York, NY, 1991.

Sirtori C, Kuhlmann J, Tillement J-P, Vrhovac B, Reidenberg MM., eds. Clinical Pharmacology. McGraw-Hill, London, 2001.

Publications

Original Research in Refereed Journals

1. Hartman, J.D. and Reidenberg, M.M.: Comparison of the glycolytic activity of blood and exudate leucocytes. *J. Appl. Physiol.*, 12:477-481, 1958.
2. Reidenberg, M.M., Ohler, E.A., and Sevy, R.W.: Cardiovascular responses to norepinephrine in acute adrenal insufficiency. *Proc. Soc. Exper. Biol. and Med.*, 97:889-892, 1958.
3. Soloff, L.A., Reidenberg, M.M., Winters, W.L. Jr., and Bello, C.T.: Clinical experiences with bretylium tosylate. *Ann. N.Y. Acad. Sci.*, 88(4):1003-1010, 1960.
4. Reidenberg, M.M. and Sevy, R.W.: Effect of adrenocortical steroids on bone electrolyte metabolism. *Proc. Soc. Exper. Biol. and Med.*, 107:132-134, 1961.
5. Reidenberg, M.M., Ohler, E.A., Sevy, R.W., and Harakal, C.: Hemodynamic changes in adrenalectomized dogs. *Endocr.*, 72:918-923, 1963.
6. Reidenberg, M.M. and Barry, W.E.: Low molecular weight dextran. *Lancet*, 1:988-989, 1964.
7. Adler, M.W., Reidenberg, M.M., Harakal, C., Rusy, B.F., and Papacostas, C.A.: Cardiovascular effects of hexafluorodiethyl ether. *Int. J. Neuropsychiatry*, 1:511-512, 1965.
8. Harakal, C., Reidenberg, M.M., Sevy, R.W., and Ohler, E.A.: Hemodynamic effects of adrenal medullectomy in the dog. *Am. J. Physiol.*, 210:5-6, 1966.
9. Reidenberg, M.M., Haag, B.L., Channick, B.J., Shuman, C.R., and Wilson, G.G.: The response of bone to metabolic acidosis in man. *Metabolism*, 15:236-241, 1966.
10. Molthan, L., Reidenberg, M.M., and Eichman, M.F.: Positive direct Coombs' tests due to cephalothin. *New Engl. J. Med.*, 277:123-125, 1967.
11. Barrera, F., Reidenberg, M.M., and Winters, W.L.: Pulmonary function in obese patients. *Am. J. Med. Sci.*, 254:785-796, 1967.
12. Haag, B.L., Reidenberg, M.M., Shuman, C.R., and Channick, B.J.:

- Aldosterone, 17-ketosteroid, and fluid and electrolyte responses to starvation and selective refeeding. *Am. J. Med. Sci.*, 254:652-658, 1967.
13. Reidenberg, M.M.: Registry of adverse drug reactions. Report of the drug reaction registry subcommittee of The Greater Philadelphia Committee for Medical-Pharmaceutical Sciences. *J.A.M.A.*, 203:31-43, 1968.
 14. Reidenberg, M.M., Sevy, R.W., and Cucinotta, A.J.: Hypercalciuria during acidosis in hypoparathyroidism. *Proc. Soc. Exper. Biol. and Med.*, 127:1-3, 1968.
 15. Harakal, C., Sevy, R.W., Reidenberg, M.M., and Faust, R.E.: Effect of adrenal medullectomy and total adrenalectomy on the hemodynamic responses to tyramine. *J. Pharmacol. Exper. Ther.*, 160:292-299, 1968.
 16. Reidenberg, M.M. and Lowenthal, D.T.: Adverse nondrug reactions. *New Engl. J. Med.*, 279:678-679, 1968.
 17. Reidenberg, M.M., Kostenbauder, H., and Adams, W.P.: The rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients. *Metabolism*, 18:209-213, 1969.
 18. Barrera, E.F., Reidenberg, M.M., Winters, W.L., and Hungspreugs, S.: Ventilation perfusion relationships in the obese patient. *J. Appl. Physiol.*, 26:420-426, 1969.
 19. Magargal, L.E., Magargal, H., and Reidenberg, M.M.: Effect of steroid hormones on the parathyroid hormone dose-response curve. *J. Pharmacol. and Exper. Ther.*, 169(1):138-141, 1969.
 20. Coleman, E.H. and Reidenberg, M.M.: Effect of thyroparathyroidectomy on skeletal sodium in the rat. *Endocrinology*, 85:175-176, 1969.
 21. Glauser, S.C., Glauser, E.M., Reidenberg, M.M., Rusy, B.F., and Tallarida, R.J.: Metabolic changes associated with the cessation of cigarette smoking. *Arch. Environ. Health*, 20:377-381, March, 1970.
 22. Reidenberg, M.M., Odar-Cederlof, I., Von Bahr, C., Borga, O., Sjoqvist, F.: Protein binding of diphenylhydantoin and desmethylinipramine in plasma from patients with poor renal function. *New Engl. J. Med.*, 285:264-267, 1971.
 23. Lowenthal, D.T. and Reidenberg, M.M.: The heart rate response to

- atropine in uremic patients, obese subjects before and during fasting, and patients with other chronic illnesses. *Proc. Soc. Exper. Biol. and Med.*, 139(2):390-393, 1972.
24. Reidenberg, M.M., James, M., and Dring, L.G.: The rate of procaine hydrolysis in serum from normal subjects and diseased patients. *Clin. Pharmacol. and Ther.*, 13:279-284, 1972.
 25. James, M., Smith, R.L., Williams, R.T., and Reidenberg, M.M.: The conjugation of phenylacetic acid in man, subhuman primates, and some non-primate species. *Proceedings of The Royal Society B*, 182:25-35, 1972.
 26. Reidenberg, M.M.: The procaine esterase activity of serum from different mammalian species. *Proc. Soc. Exper. Biol. and Med.*, 140:1059-1061, 1972.
 27. Drayer, D.E. and Reidenberg, M.M.: Metabolism of tetralin and toxicity of Cuprex^(R) in man. *Drug Metabolism and Disposition*, 1:577-579, 1973.
 28. Lowenthal, D.T., Chardo, F., and Reidenberg, M.M.: Removal of mercury by peritoneal dialysis. *Arch. Int. Med.*, 134:139-141, 1974.
 29. Reidenberg, M.M., Drayer, D.E., DeMarco, A.L., and Bello, C.T.: Hydralazine elimination in man. *Clin. Pharmacol. and Ther.*, 14:970-977, 1973.
 30. Reidenberg, M.M., Shear, L., and Cohen, R.V.: Elimination of isoniazid in patients with impaired renal function. *Am. Review of Respir. Dis.*, 108:1426-1428, 1973.
 31. Reidenberg, M.M. and Martin, J.H.: The acetylator phenotype of patients with systemic lupus erythematosus. *Drug Metabolism and Disposition*, 2:71-73, 1974.
 32. Kessler, K.M., Lowenthal, D.T., Warner, H., Gibson, T., Briggs, W., and Reidenberg, M.M.: Quinidine elimination in patients with congestive heart failure or poor renal function. *New Engl. J. Med.*, 290:706-709, 1974.
 33. Drayer, D.E., Reidenberg, M.M., and Sevy, R.W.: N-acetylprocainamide: An active metabolite of procainamide. *Proc. Soc. Exper. Biol. and Med.*, 146:358-363, 1974.

34. Drayer, D.E., Strong, J.M., Jones, B., Sandler, A., and Reidenberg, M.: In vitro acetylation of drugs by human blood cells. *Drug Metabolism and Distribution*, 2:499-505, 1974.
35. Affrime, M. and Reidenberg, M.M.: The protein binding of some drugs in plasma from patients with alcoholic liver disease. *Eur. J. Clin. Pharmacol.*, 8:267-269, 1975.
36. Reidenberg, M.M., Drayer, D.E., Levy, M., and Warner, H.: The polymorphic acetylation of procainamide by man. *Clin. Pharmacol. Ther.*, 17:722-730, 1975.
37. Reidenberg, M.M. and Vesell, E.S.: Unaltered metabolism of antipyrine and tolbutamide during fasting in man. *Clin. Pharmacol. Ther.*, 17:650-656, 1975.
38. Reidenberg, M.M. and Caccese, R.W.: Lymphocyte transformation tests and suspected drug allergy. *J. Lab. Clin. Med.*, 86:997-1002, 1975.
39. Cerletti, C., Keinath, S.H., Reidenberg, M.M., and Adler, M.: Relationship between method of morphine administration, plasma levels, and the withdrawal syndrome in rats. *Pharmacol., Biochem., and Behavior*, 4:323-327, 1976.
40. Bagwell, E.E., Walle, T., Drayer, D.E., Reidenberg, M.M., Pruett, J.K.: Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog. *J. Pharmacol. Exper. Ther.*, 197:38-48, 1976.
41. White, R.P., Sealey, J., Reidenberg, M.M., Stenzel, K.H., Sullivan, J.F., David, D.S., Laragh, J.H., and Rubin, A.L.: Mechanisms of blood pressure control in anephrics: plasma renin and dopamine B hydroxylase activity. *Trans. Amer. Soc. Artif. Int. Organs*, 22:420-423, 1976.
42. Chami, J., Reidenberg, M., Wellner, D., David, D.S., Rubin, A., and Stenzel, K.H.: Essential amino acid metabolism in maintenance dialysis patients. *Trans. Amer. Soc. Artif. Int. Organs*, 22:168-173, 1976.
43. Reidenberg, M.M., Lowenthal, D.T., Briggs, W., and Gasparo, M.: Pentobarbital elimination in patients with poor renal function. *Clin. Pharmacol. Ther.*, 20:67-71, 1976.
44. Drayer, D.E., Cordova, M., Slaven, B.H., Bagwell, E.E., and Reidenberg, M.M.: The antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl)

- benzamide (the p-hydroxy isostere of procainamide) in dogs and mice. *J. Med. Chem.*, 20:270-274, 1977.
45. Tapia, L., Cheigh, J.S., David, D.S., Sullivan, J.F., Saal, S., Reidenberg, M.M., Stenzel, K.H., and Rubin, A.L.: Treatment of pruritus in dialysis patients with parenteral lidocaine. *New Engl. J. Med.*, 296:261-262, 1977.
 46. Szeto, H.H., Inturrisi, C.E., Houde, R., Saal, S., Cheigh, J., Reidenberg, M.M.: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. *Ann. Int. Med.*, 86:738-741, 1977.
 47. Drayer, D.E., Lowenthal, D.T., Woosley, R.L., Nies, A.S., Schwartz, A., and Reidenberg, M.M.: Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. *Clin. Pharmacol. Ther.*, 22:63-69, 1977.
 48. Saudek, C.D., Werns, S., and Reidenberg, M.M.: Phenytoin in the treatment of diabetic symmetrical polyneuropathy. *Clin. Pharmacol. Ther.* 22:196-199, 1977.
 49. Drayer, D.E., Restivo, K., and Reidenberg, M.M.: Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high pressure liquid chromatography. *J. Lab. Clin. Med.*, 90:816-822, 1977.
 50. Romankiewicz, J.A., Reidenberg, M.M., Drayer, D.E., and Franklin, J.E.: The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: An approach to control quinidine induced diarrhea. *Amer. Heart J.*, 96:518-521, 1978.
 51. Reidenberg, M.M., Levy, M., Warner, H., Coutinho, C.B., Schwartz, M.A., Yu, G., and Cheripko, J.: Relationship between diazepam dose, plasma level, age, and central nervous system depression. *Clin. Pharmacol. Ther.*, 23:371-374, 1978.
 52. Drayer, D.E., Lowenthal, D.T., Restivo, K.M., Schwartz, A., Cook, C.E., and Reidenberg, M.M.: Steady state serum levels of quinidine and active quinidine metabolites in cardiac patients with varying degrees of renal function. *Clin. Pharmacol. Ther.*, 24:31-39, 1978.
 53. Woosley, R.L., Drayer, D.E., Reidenberg, M.M., Nies, A.S., Carr, K., and Oates, J.A.: Effect of acetylator phenotype on the rate at which

- procainamide induces antinuclear antibodies and the lupus syndrome. *New Engl. J. Med.*, 298:1157-1159, 1978.
54. Dietrich, J., Krauss, A.N., Reidenberg, M.M., Drayer, D.E., and Auld, P.A.M.: Alterations in state in apneic pre-term infants receiving theophylline. *Clin. Pharmacol. Ther.*, 24:474-478, 1978.
 55. Jones, B.R., Baran, A., and Reidenberg, M.M.: Evaluating patients' warfarin requirements. *J. Amer. Geriatrics Soc.*, 28:10-12, 1980.
 56. Meyers, T.F., Milsap, R.L., Krauss, A.N., Auld, P.A.M., and Reidenberg, M.M.: Low dose theophylline therapy in idiopathic apnea of prematurity. *J. Ped.*, 96:99-103, 1980.
 57. Lahita, R., Kluger, J., Drayer, D.E., Koffler, D., and Reidenberg, M.M.: Antibodies to nuclear antigens in patients treated with procainamide or acetyl procainamide. *New Engl. J. Med.*, 301:1382-1385, 1979.
 58. Drayer, D.E., Hughes, M., Lorenzo, B., and Reidenberg, M.M.: The prevalence of high (3S)-3-hydroxyquinidine/quinidine ratios in serum and the clearance of quinidine in cardiac patients of varying ages. *Clin. Pharmacol. Ther.*, 27:72-75, 1980.
 59. Jones, B.R., Bhalla, R.B., Mladek, J., Kaleya, R.N., Gralla, R.J., Alcock, N.W., Schwartz, M.K., Young, C.W., and Reidenberg, M.M.: Comparison of methods of evaluating nephrotoxicity of cis-platinum. *Clin. Pharmacol. Ther.*, 27:557-562, 1980.
 60. Kluger, J., Drayer, D., Reidenberg, M.M., Ellis, G., Lloyd, V., Tyberg, T., and Hayes, J.: The clinical pharmacology and antiarrhythmic efficacy of acetyl procainamide in patients with arrhythmias. *Amer. J. Cardiol.*, 45:1250-1257, 1980.
 61. Merle, L.J., Reidenberg, M.M., Camacho, M.T., Jones, B.R., and Drayer, D.E.: Renal injury in patients with rheumatoid arthritis treated with gold. *Clin. Pharmacol. Ther.*, 28:216-222, 1980.
 62. Reidenberg, M.M. and Restivo, K.: The binding of theophylline to serum proteins of hemodialysis patients. *J. Dialysis*, 3:375-381, 1979.
 63. Cerletti, C., Keinath, S., Tallarida, R., Reidenberg, M.M., and Adler, M.W.: Morphine concentrations in the rat after intraperitoneal or

- subcutaneous injection. *Substance and Alcohol Misuse*, 1:65-70, 1980.
64. Reidenberg, M.M., Levy, M., Drayer, D.E., Zylber-Katz, E., and Robbins, W.C.: Acetylator phenotype in idiopathic systemic lupus erythematosus. *Arthritis and Rheum.*, 23:569-573, 1980.
 65. Guggenheim, R. and Reidenberg, M.M.: Serum digoxin concentration and age. *J. Amer. Geriatrics Soc.*, 28:553-555, 1980.
 66. Reidenberg, M.M., Camacho, M., Kluger, J., and Drayer, D.E.: Aging decreases the renal clearance of procainamide and acetyl procainamide. *Clin. Pharmacol. Ther.*, 28:732-735, 1980.
 67. Kluger, J., Drayer, D.E., Reidenberg, M.M., and Lahita, R.: Acetyl procainamide therapy in patients with previous procainamide-induced lupus syndrome. *Ann. Int. Med.*, 95:14-18, 1981.
 68. Drayer, D.E., Lorenzo, B., and Reidenberg, M.M.: Liquid chromatography and fluorescence spectroscopy compared with a homogeneous enzyme immunoassay technique for determining quinidine in serum. *Clin. Chem.*, 27:308-310, 1981.
 69. Linday, L.A., Levin, A.R., Klein, A.A., Reidenberg, M.M., and Engle, M.A.: Effect of vasodilators on left-to-right shunts in infants and children. *Ped. Pharmacol.*, 1:267-278, 1981.
 70. Rodman, J.S. and Reidenberg, M.M.: Symptomatic hypokalemia resulting from surreptitious diuretic ingestion. *J.A.M.A.*, 246:1687-1689, 1981.
 71. Jones, B.R., Gordon, C.S., Umans, J., Reidenberg, M.M., and Young, C.W.: Kinetics of metoprine, a lipid-soluble antifolate. *Brit. J. Clin. Pharmacol.*, 12:675-680, 1981.
 72. Kluger, J., Leech, S., Reidenberg, M.M., Lloyd, V., and Drayer, D.E.: Long-term antiarrhythmic therapy with acetyl procainamide. *Amer. J. Cardiol.*, 48:1124-1132, 1981.
 73. Drayer, D.E., Romankiewicz, J., Lorenzo, B., and Reidenberg, M.M.: Aging and the renal clearance of cimetidine. *Clin. Pharmacol. Ther.*, 31:45-50, 1982.
 74. Linday, L.A., Engle, M.A., and Reidenberg, M.M.: The relationship between maturation and the renal clearance of digoxin. *Clin. Pharmacol. Ther.*, 30:735-738, 1981

75. Reynolds, R.D., Burmeister, W.E., Calzadilla, S.V., Lee, R.J., Reidenberg, M.M., and Drayer, D.E.: Comparison of antiarrhythmic effects of procainamide, N-acetylprocainamide, and p-hydroxy-N-(3-diethylaminopropyl) benzamide. *Proc. Soc. Exper. Biol. and Med.*, 169:156-160, 1982.
76. Kluger, J. Horner, H., and Reidenberg, M.M.: Effects of procainamide and N-acetylprocainamide on myocardial contractility in ischemic isolated rabbit hearts. *Proc. Soc. Exper. Biol. and Med.*, 168:350-355, 1981.
77. Drayer, D.E., Lorenzo, B., Lahita, R.G., Robbins, W.C., and Reidenberg, M.M.: Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. *Clin. Pharmacol. Ther.*, 32:195-200, 1982.
78. Powell, J.H. and Reidenberg, M.M.: In vitro response of rat and human kidney lysosomes to aminoglycosides. *Biochem. Pharmacol.*, 31:3447-3453, 1982.
79. Kaiko, R.F., Foley, K.M., Grabinski, P.Y., Heidrich, G., Rogers, A.G., Inturrisi, C.E., and Reidenberg, M.M.: Central nervous system excitatory effects of meperidine in cancer patients. *Ann. of Neurology*, 13:180-185, 1983.
80. Reidenberg, M.M., Durant, P.J., Harris, R.A., De Boccardo, G., Lahita, R., and Stenzel, K.H.: A case of lupus erythematosus-like illness due to hydrazine. *Amer. J. Med.*, 75:365-370, 1983.
81. Drayer, D.E., Lorenzo, B., Werns, S., and Reidenberg, M.M.: Plasma level, protein-binding, and elimination data for lidocaine and active metabolites in cardiac patients of various ages receiving lidocaine. *Clin. Pharmacol. Ther.*, 34:14-22, 1983.
82. Sherman, R.L., Drayer, D.E., Leyland-Jones, B.R., and Reidenberg, M.M.: The urinary excretion of N-acetyl- β -glucosaminidase and β_2 microglobulin in patients with renal parenchymal disease. *Arch. Int. Med.*, 143:1183-1185, 1983.
83. Powell, J.H. and Reidenberg, M.M.: Further studies of the response of kidney lysosomes to aminoglycosides and other cations. *Biochem. Pharmacol.*, 32:3213-3220, 1983.

84. Linday, L.A., Drayer, D.E., Ali Khan, M.A., Cicalese, C., and Reidenberg, M.M.: Pubertal changes in net renal tubular secretion of digoxin. *Clin. Pharmacol. Ther.*, 35:438-446, 1984.
85. Alderman, M.H., Melcher, L., Drayer, D.E., and Reidenberg, M.M.: Increased excretion of urinary N-acetyl- β -glucosaminidase in essential hypertension and its decline with hypotensive therapy. *New Engl. J. Med.*, 09:1213-1217, 1983.
86. Meyer, B.R., Lewin, M., Drayer, D.E., Pasmantier, M., Lonski, L., and Reidenberg, M.M.: Optimizing metoclopramide control of cis-platin-induced emesis. *Ann. Int. Med.*, 100:393-395, 1984.
87. Meyer, B.R., Fishbein, A., Rosenman, K., Lerman, Y., Drayer, D.E., and Reidenberg, M.M.: Increased urinary enzyme excretion from workers exposed to nephrotoxic chemicals. *Amer. J. Med.*, 76:989-998, 1984.
88. Reidenberg, M.M., Case, D.B., Drayer, D.E., Reis, S., and Lorenzo, B.: Development of antinuclear antibody in patients with high doses of captopril. *Arthritis Rheum.*, 27:579-581, 1984.
89. Powell, J.H. and Reidenberg, M.M.: In vitro response of hepatic lysosomes to endogenous and exogenous compounds. *Proc. Soc. Exper. Biol. and Med.*, 176:346-349, 1984.
90. Meyer, B.R., Lewin, M., Pasmantier, M., Drayer, D.E., and Reidenberg, M.M.: Metoclopramide and chemotherapy-induced emesis. *Ann. Int. Med.*, 101:141, 1984.
91. deBoccardo, G., Drayer, D.E., Rubin, A., Novogrodsky, A., Reidenberg, M.M., and Stenzel, K.: Inhibition of pokeweed mitogen-induced B cell differentiation by compounds containing primary amine or hydrazine groups. *Clin. Exp. Immunol.*, 59:69-76, 1985.
92. Aucoin, D.P., Peterson, M.E., Hurvitz, A.I., Drayer, D.E., Lahita, R.G., Quimby, F.W., and Reidenberg, M.M.: Propylthiouracil-induced immune-mediated disease in cats. *J. Pharmacol. Exper. Ther.*, 234:13-18, 1985.
93. Notterman, D.A., Drayer, D.E., Metakis, L., and Reidenberg, M.M.: Stereoselective renal tubular secretion of quinidine and quinine in humans. *Clin. Pharmacol. Ther.*, 40:511-517, 1986.

94. Leipzig, R.M., Goodman, H., Gray, G., Erle, H., and Reidenberg, M.M.: Reversible narcotic-associated mental status impairment in patients with metastatic cancer. *Pharmacology*, 35:47-54, 1987.
95. Restivo, K.M., Drayer, D.E., Orto, L., Bond, O., and Reidenberg, M.M.: The accumulation of polyamines and their weak association with lower body temperature in elderly convalescent patients. *J. Lab. Clin. Med.*, 110:217-220, 1987.
96. Meyer, B.R., O'Mara, V., and Reidenberg, M.M.: A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. *J. Clin. Oncol.*, 5:1994-1997, 1987.
97. Aucoin, D.P., Rubin, R.L., Peterson, M.E., Reidenberg, M.M., Drayer, D.E., Hurvitz, A.I., and Lahita, R.G.: Dose dependent induction of anti-native DNA antibodies by propylthiouracil in cats. *Arthritis and Rheum.*, 31:688-692, 1988.
98. Reidenberg, M.M., Goodman, H., Erle, H., Gray, G., Lorenzo, B., Leipzig, R.M., Meyer, B.R., and Drayer, D.E.: Hydromorphone levels and pain control in patients with severe chronic pain. *Clin. Pharmacol. Ther.*, 44:376-382, 1988.
99. Reidenberg, M.M., Lorenzo, B.J., Drayer, J.K., Nestor, T., Regnier, J.C., Kowal, B.A., and Bekersky, I.: A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline. *Ther. Drug Monitoring*, 10:434-437, 1988.
100. Jennings, M.B. and Reidenberg, M.M.: Adaptation to Nephrotoxic Chemicals. *Proc. Soc. Exper. Biol. and Med.*, 189:338-343, 1988.
101. Drayer, D.E. and Reidenberg, M.M.: Gossypol and Na⁺, K⁺ ATPase from human erythrocytes. *Contraception*, 38:579-583, 1988.
102. Wu, D.F., Reidenberg, M.M., and Drayer, D.E.: Determination of gossypol enantiomers in plasma after administration of racemate using high performance liquid chromatography with precolumn chemical derivatisation. *J. Chromatogr.*, 433:141-148, 1988.
103. Ganley, C.J., Paget, S.A., Reidenberg, M.M.: Increased renal tubular cell excretion by patients receiving chronic therapy with gold and nonsteroidal anti-inflammatory drugs. *Clin Pharmacol Ther*, 46:51-55, 1989.

104. Lorenzo, B., Reidenberg, M.M.: Potential artifacts in the use of caffeine to determine acetylation phenotype. *Br. J. Clin Pharmacol*, 28:207, 1989.
105. Wu, D.F., Griffith O.W., Reidenberg, M.M.: Lack of effect of glutathione depletion by L-Buthionine-S, R-sulfoximine on gentamicin nephrotoxicity in rats. *Pharmacology*, 40:250-257, 1990.
106. Notterman, D.A., Greenwald, B.M., Moran, F., DiMaio-Hunter, A., Metakis, L., Reidenberg, M.M.: Dopamine clearance in critically ill infants and children: Effect of age and organ system dysfunction. *Clin. Pharmacol. Ther.*, 48:138-147, 1990.
107. Wu, D.F., Reidenberg, M.M.: Stereoselective interaction between gossypol and rat plasma. *Contraception*, 41:377-388, 1990.
108. Sang, G.W., Lorenzo, B., Reidenberg, M.M.: Inhibitory effects of gossypol on corticosteroid 11-beta-hydroxysteroid dehydrogenase from guinea pig kidney: A possible mechanism for causing hypokalemia. *J. Steroid Biochemistry and Molecular Biology*, 39:169-176, 1991.
109. Aulitzky, W.K., Schlegel, P.N., Wu, D.F., et al: Measurement of urinary clusterin as an index of nephrotoxicity. *Proc. Soc. Exper. Biol. and Med.*, 199:93-96, 1992.
110. Song, D.J., Lorenzo, B., Reidenberg, M.M.: Inhibition of 11- β -hydroxysteroid dehydrogenase by gossypol and bioflavonoids. *J. Lab Clin Med*, 120:792-797, 1992.
111. Reidenberg, M.M., Gu, Z.P., Lorenzo, B.J., et al: Differences in serum potassium concentrations in normal men in different geographic locations. *Clin Chem*, 39:72-75, 1993.
112. Flack, M.R., Pyle, R.G., Mullen, N.M., Lorenzo, B.J., Wu, Y.W., Knazek, R.A., Nisula, B.C., Reidenberg, M.M.: Oral gossypol in the treatment of metastatic adrenal cancer. *J Clin Endocr & Metab*, 76:1019-1024, 1993.
113. Eti, S., Cheng, C.Y., Marshall, A., Reidenberg, M.M.: Urinary clusterin in chronic nephrotoxicity in the rat. *Proc. Soc. Exper. Biol. & Med.*, 202:487-490, 1993.
114. Reidenberg, M.M., Drayer, D.E., Lorenzo, B.J., Strom, B.L., West, S.L., Snyder, E.S., Freundlick, B., Stolley, P.D.: Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. *Arth. Rheum.*, 36:971-973, 1993.
115. Dreisbach, A.W., Greif, R.L., Lorenzo, B.J., Reidenberg, M.M.: Lipophilic beta-blockers inhibit rat skeletal muscle mitochondrial respiration. *Pharmacology*, 47:295-299, 1993.
116. Strom, B.L., Reidenberg, M.M., Freundlick, B., Schinnar, R.: Breast silicone implants and

- risk of systemic lupus erythematosus. *J. Clin. Epidemiol.*, 47:1211-1214, 1994.
117. Wu, D., Reidenberg, M.M.: Effect of potassium deficiency and gossypol on urinary N-acetyl- β -glucosaminidase excretion in the rat. *Contraception*, 48:513-516, 1993.
 118. Gu, Z-P., Segal, S., Reidenberg, M.M.: Serum potassium values in normal men in Shanghai compared with men from Shanghai living abroad. *Clin Chem*, 40:340, 1994.
 119. Zhang, Yin Di, Lorenzo, B.J., Reidenberg, M.M.: Inhibition of 11 β -hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringin and some other compounds. *J. Steroid Biochem. & Molec. Biol.*, 49:81-85, 1994.
 120. Ganley, C.J., Nguyen, H.T., Reidenberg, M.M.: The effect of vitamin B₆ deficiency on acetylhydrazine hepatic necrosis. *Pharmacology & Toxicology*, 74:303-304, 1994.
 121. Strom, B.L., Reidenberg, M.M., West, S., Snyder, E.S., Freundlich, B., Stolley, P.: Shingles, allergies, family history, oral contraceptives and other potential risk factors for systemic lupus erythematosus. *Amer. J. Epidemiol.*, 140:632-642, 1994.
 122. Eti, S., Weisman, R., Hoffman, B., Reidenberg, M.M.: Slight renal effect of mercury from amalgam fillings. *Pharmacology and Toxicology*, 76:47-49, 1995.
 123. Santini, D.L., Lorenzo, B.J., Koufis, T., Reidenberg, M.M.: Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics. *Amer. J. Hypertension*, 8:516-519, 1995.
 124. Lee, Y., S., Lorenzo, B.J., Reidenberg, M.M.: Grapefruit juice and its flavonoids inhibit 11 β -hydroxysteroid dehydrogenase (11 β -OHS). *Clin. Pharmacol. Ther.*, 59:14-21, 1996.
 125. Krivo, S., Reidenberg, M.M.: Staff assessment of patients' pain. *New Engl J Med*, 334:59, 1996.
 126. Ligueros, M., Jeoung, D., Tang, B., Hochhauser, D., Reidenberg, M.M., Sonenberg, M.: Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1, transfected human fibrosarcoma cells. *Brit J Cancer* 76, 21-28, 1997.
 127. Lee, L.S., Reidenberg, M.M.: A method for measuring naringenin in biological fluids and its disposition from grapefruit juice by man. *Pharmacology*, 1998; 56: 314-317.
 128. Guo, J., Reidenberg, M.M.: Inhibition of 11 β -hydroxysteroid dehydrogenase by bioflavonoids and their interaction with furosemide and gossypol. *J Lab Clin Med* 1998; 132: 32-38.
 129. Drayer, R.A., Henderson, J., Reidenberg, M.M.: Barriers to better pain control in

- hospitalized patients. *J. Pain & Symptom Mgmt.* 1999; 17:434-39.
130. Bushunow, P., Reidenberg, M.M., Wasenko, J., Winfield, J., Lorenzo, B., Lemke, S., Himpler, B., Corona, R., Coyle T.: Gossypol treatment of recurrent adult malignant gliomas. *J. Neuro-Oncology* 1999; 43:79-86..
 131. Coutinho, EM, Athayde, C., Alta, G., et al. Gossypol blood levels and inhibition of spermatogenesis in men taking gossypol as an alternative to vasectomy. *Contraception*, 2000, 61:61-67.
 132. VanPoznak, C., Seidman, A.D., Reidenberg, M.M., et al. Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. *Breast Cancer Research and Treatment*, 2001; 66:239-248.
 133. Qiu JP, Levin LR, Buck J, Reidenberg MM. Different Pathways of Cell Killing by Gossypol Enantiomers. *Exper Biol & Med*, 2002;227:398-401.
 134. Richard J, Reidenberg MM. The risk of disciplinary action by state medical boards against physicians prescribing opioids. *J Pain & Symptom Mgt.*, 2005, 29:206-212.
 135. Reidenberg MM. Statins, lack of energy, and ubiquinone. (Letter) *Br J Clin Pharmacol*, 2005; 59:606-7.
 136. Jung B, Reidenberg MM. The risk of action by the DEA against physicians prescribing opioids for pain. *Pain Medicine*, 2006; 7:353-357.
 137. Jung BF, Reidenberg MM. Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies. *Clin Pharmacol Ther* 2005; 77:324-34.
 138. Reidenberg MM, Willis O. Prosecutions of physicians for prescribing opioids. *Clin Pharmacol Ther.* 2007; 81: 903-906.

Patent

1. Flack MR, Knazek R, Reidenberg M. Gossypol acetic acid for the treatment of cancer. U.S. Patent 5,385,936 issued January 31, 1995.
2. Flack MR, Knazek R, Reidenberg M. Gossypol for the treatment of cancer. U.S. Patent 6,114,397 issued September 5, 2000.

- 3 Flack MR, Knazek R, Reidenberg M. Gossypolone for the treatment of cancer. U.S. Patent RE40,862 issued July 21, 2009.

Case Reports

1. Reidenberg, M.M.: A case of apparent photosensitization due to pyrvinium pamoate. *Amer. J. Trop. Med., and Hygiene*, 11:717, 1962.
2. Wolfe, R.C., Reidenberg, M.M., and Vispo, R.H.: Propoxyphene (Darvon) addiction and withdrawal syndrome. *Ann. Int. Med.*, 70(4):773-776, 1969.
3. Wolfe, R.C., Reidenberg, M.M., and Dinoso, V.: Tang^(R) and methadone by vein. *Ann. Int. Med.*, 72:830, 1972.
4. Ballek, R.E., Reidenberg, M.M., and Orr, L.: Inhibition of diphenylhydantoin metabolism by chloramphenicol. *Lancet*, 1:150, 1973.
5. Reidenberg, M.M. and Katz, M.A.: Slow extrarenal excretion of digoxin (letter to editor). *New Engl. J. Med.*, 289:1148, 1973.
6. Gotz, V.P., Drayer, D.E., Schned, E.S., and Reidenberg, M.M.: An unusual cause of theophylline toxicity. *New York State J. Med.*, 79:1232-1234, 1979.
7. Demayo AP, Reidenberg MM. Grand mal seizure in a child 30 minutes after cyclogyl (Cyclopentolate hydrochlorides) and 10% Neo-synephrine (phenylephrine hydrochlorid) eye drops were instilled. *Pediatrics*, 2004;113:e499-e500.
8. Siegler E, Reidenberg MM. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. *Clin Pharm Ther*, 2004; 5:484-88.

Reviews and Other Publications

1. Reidenberg, M.M.: The role of bone in electrolyte metabolism. *A.M.A. Arch. Int. Med.*, 107:578-582, 1961.
2. Reidenberg, M.M., Powers, D.V., Sevy, R.W., and Bello, C.T.: Acute

- renal failure due to nephrotoxins. *Amer. J. Med. Sci.*, 247:25-29, 1964.
3. Reidenberg, M.M.: Adverse drug reactions without drugs. *Lancet*, 11:892, 1967.
 4. Reidenberg, M.M.: Effect of kidney disease on pharmacokinetics and drug response. *Proceedings of the Fifth International Congress of Pharmacology*, 3:174-181, 1973.
 5. Reidenberg, M.M. and Affrime, M.: Influence of disease on binding of drugs to plasma proteins. *Ann. N.Y. Acad. Sci.*, 226:115-126, 1973.
 6. Reidenberg, M.M.: The Adrenal Medulla. In Shuman, C.R., editor, Practice of Medicine, Harper and Row, Hagerstown, MD, 8(Chap. 31), 1972.
 7. Reidenberg, M.M.: Effect of excretion changes on drug action and drug interactions. In Garattini, S., editor, Symposium on Drug Interactions, Raven Press, NY, pp. 41-49, 1974.
 8. Reidenberg, M.M.: Kidney disease and drug metabolism. *Medical Clinics of North America*, 58:1059-1062, 1974.
 9. Reidenberg, M.M.: Effect of disease states on plasma protein binding of drugs. *Medical Clinics of North America*, 58:1103-1109, 1974.
 10. Feldman, S. and Reidenberg, M.M.: Stability of aspirin in propoxyphene compound dosage forms (letter to editor). *New Engl. J. Med.*, 291:211, 1974.
 11. Sevy, R.W., Harakal, C., and Reidenberg, M.M.: Cardiovascular Function in Adrenal Insufficiency. In Glenn, T.M., editor, Steroids and Shock, University Park Press, Baltimore, MD, pp. 9-32, 1974.
 12. Drayer, D.E., Strong, J.M., and Reidenberg, M.M.: The role of gas chromatography - mass spectrometry in a clinical pharmacology program. In Frigerio, A. and Castagnoli, N., editors, Advances in Mass Spectrometry in Biochemistry and Medicine, Spectrum Publications, New York, pp. 553-563, 1976.
 13. Reidenberg, M.M.: The effects of the kidney on drug actions and drug interactions. In Grahame-Smith, D.G., editor, Drug Interactions, Macmillan, London, pp. 209-215, 1977.
 14. Reidenberg, M.M.: Drug metabolism in uremia. *Clin. Nephrology*, 4:83-85, 1975.

15. Reidenberg, M.M.: A mechanism for the evaluation of the importance of research results. *J.I.R.*, 21:3, 1974.
16. Reidenberg, M.M.: The binding of drugs to plasma proteins from patients with poor renal function. *Clin. Pharmacokinetics*, 1:121-125, 1976.
17. Reidenberg, M.M.: Some extraneuronal interactions of drugs of abuse: an overview. *Ann. N.Y. Acad. Sci.*, 281:1-10, 1976.
18. Laskin, O.L., Romankiewicz, J.A., and Reidenberg, M.M.: Changing digitalis glycosides in an average size adult (ltr.). *Amer. Heart J.*, 93:266-267, 1977.
19. Reidenberg, M.M.: The biotransformation of drugs in renal failure. *Amer. J. Med.*, 62:482-485, 1977.
20. Reidenberg, M.M.: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. *Amer. J. Med.*, 62:466-470, 1977.
21. Reidenberg, M.M.: Obesity and fasting - effects on drug metabolism and drug action in man. *Clin. Pharmacol. Ther.*, 22:729-734, 1977.
22. Reidenberg, M.M. and Drayer, D.E.: Drug metabolism and active drug metabolites in renal failure. *J. Dialysis*, 1:313-318, 1977.
23. Reidenberg, M.M.: Views of an academician. In Gouveia, Tognoni, and Van der Kleijn, editors, Clinical Pharmacy and Clinical Pharmacology, North Holland Publishing Co., Amsterdam and New York, pp. 443-448, 1976.
24. Reidenberg, M.M.: Compliance in management: The use of plasma level determinations. In Onesti, G. and Lowenthal, D.T., editors, The Spectrum of Antihypertensive Drug Therapy, Biomedical Information Corp., New York, pp. 65-68, 1977.
25. Drayer, D.E. and Reidenberg, M.M.: Clinical consequences of polymorphic acetylation of basic drugs. *Clin. Pharmacol. Ther.*, 22:251-258, 1977.
26. Reidenberg, M.M. and Drayer, D.E.: Effects of renal disease upon drug disposition. *Drug Metabolism Reviews*, 8:293-302, 1978.
27. Romankiewicz, J.A. and Reidenberg, M.M.: Factors that modify drug

- absorption. *Rational Drug Therapy*, 12(No. 10), 1978.
28. Reidenberg, M.M., Drayer, D.E., and Robbins, W.C.: Polymorphic drug acetylation and systemic lupus erythematosus. *Advances in Pharmacology and Therapeutics*, 6:51-56, 1978.
 29. Reidenberg, M.M.: Individualization of drug therapy in patients with renal disease. In Lowenthal, D.T. and Major, D.A., editors, Clinical Therapeutics, Grune and Stratton, New York, pp. 97-102, 1978.
 30. Reidenberg, M.M. and Drayer, D.E.: Aromatic amines and hydrazines, drug acetylation, and lupus erythematosus. *Human Genetics, Suppl.*, 1:57-63, 1978.
 31. Reidenberg, M.M. and Drayer, D.E.: Drug therapy in renal failure. *Ann. Rev. Pharmacol. Toxicol.*, 20:45-54, 1980.
 32. Drayer, D.E., Kluger, J., Lahita, R., and Reidenberg, M.M.: Theoretical basis for interest in acetylprocainamide and clinical experience with this new antiarrhythmic agent. *Drug Metabolism Rev.*, 10:239-246, 1979.
 33. Reidenberg, M.M.: Adverse drug reactions: Special cases of chemically-induced disease. *Trends in Pharmacological Sciences*, 1:180-181, 1980.
 34. Reidenberg, M.M.: Drugs in the elderly. *Bull. N.Y. Acad. Med.*, 56:703-714, 1980.
 35. Reidenberg, M.M.: The chemical induction of systemic lupus erythematosus and lupus-like illnesses. *Arthritis and Rheumatism*, 24:1004-1008, 1981.
 36. Reidenberg, M.M.: Is protein binding important? In Richens, A. and Marks, V., editors, Therapeutic Drug Monitoring, Churchill Livingstone, London, pp. 23-30, 1981.
 37. Reidenberg, M.M.: Drugs in the elderly. *Medical Clinics of North America*, 66:1073-1078, 1982.
 38. Reidenberg, M.M.: Drug interactions and the elderly. *J. Amer. Geriatrics Soc.*, 30:S67-68, 1982.
 39. Reidenberg, M.M.: The pharmacogenetics of antiarrhythmic drugs. *Ann. N.Y. Acad. Sci.*, 432:69-74, 1984.
 40. Reidenberg, M.M. and Drayer, D.E.: Alteration of drug protein binding in

- renal disease. *Clin. Pharmacokinetics*, 9(Suppl. 1):18-26, 1984.
41. Reidenberg, M.M.: Aromatic amines and the pathogenesis of lupus and erythematosus. *Amer. J. Med.*, 75:1037-1042, 1983.
 42. Reidenberg, M.M.: Renal failure and congestive heart failure: use of drugs. *Primary Cardiology*, 9:97-104, 1983.
 43. Reidenberg, M.M., Leipzig, R.M., Goodman, H., Gray, G., and Erle, H.: Drug therapy in the teaching nursing home. In Wendland, C.J. and Schneider, E.L., editors, The Teaching Nursing Home: A New Approach to Geriatric Research, Education, and Clinical Care, Raven Press, New York, pp. 197-205, 1985.
 44. Reidenberg, M.M. and Drayer, D.E.: Genetic regulation of drug metabolism and SLE. In Lahita, R.G., editor, Systemic Lupus Erythematosus, Wiley, New York, pp. 857-868, 1987.
 45. Reidenberg, M.M.: The discipline of clinical pharmacology. *Clin. Pharmacol. Ther.*, 38:2-5, 1985.
 46. Reidenberg, M.M.: Kidney function and drug action. *New Engl. J. Med.*, 313:816-818, 1985.
 47. Reidenberg, M.M.: A review of reported adverse cardiovascular reactions to phenylpropanolamine. In Morgan, J.P., Kagan, D.V., and Brody, J.S., editors, Phenylpropanolamine, Praeger, New York, pp. 271-284, 1985.
 48. Reidenberg, M.M. and Drayer, D.E.: Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. *Angiology*, 37:968-971, 1986.
 49. Reidenberg, M.M.: A hypothesis that exogenous chemicals cause some cases of systemic lupus erythematosus. In Plaa, G.L. and Erill, S., editors, Interactions of Drugs and Chemicals in Industrial Societies, Elsevier, Amsterdam, pp. 175-180, 1987.
 50. Petrie, J.C. and Reidenberg, M.M.: Health care and patient services. *Clin. Pharmacol. Ther.*, 39:474-476, 1986.
 51. Reidenberg, M.M.: Introduction to Symposium on Cardiac Glycosides. In Doyle, E.F., et al, editors, Pediatric Cardiology, Springer Verlag, 1986.
 52. Reidenberg, M.M.: Should unevaluated therapies be available for sale?

- Clin. Pharmacol. Ther., 42:599-600, 1987.
53. Reidenberg, M.M.: Certifying Physicians in Clinical Pharmacology. Clin. Pharmacol. Ther., 43:4-5, 1988.
 54. Reidenberg, M.M.: Drug therapy in the elderly: The problem from the point of view of a clinical pharmacologist. Clin. Pharmacol. Ther., 42:677-680, 1987.
 55. Reidenberg, M.M.: The therapeutic use of stereochemically pure drugs -- a pragmatic point of view. In Wainer, I. and Drayer, D., editors, Stereochemical Aspects of Pharmacologically Active Compounds, Marcel Dekker, New York, pp. 365-369, 1988.
 56. Reidenberg, M.M.: Commentary on the tPA Controversy. J. Clin. Res. and Drug Development, in press.
 57. Reidenberg, M.M.: The drug approval process (Itr). New Engl. J. Med., 318:1618, 1988.
 58. Reidenberg, M.M.: Padding the C.V., impairing the utility and integrity of the biomedical literature. Clin. Pharmacol. Ther., 45:337-339, 1989.
 59. Reidenberg, M.M.: Pain control for patients with advanced cancer. Chinese J. of Clin. Pharmacol., 5:1-4, 1989.
 60. Reidenberg, M.M.: Clinical Pharmacology. JAMA, 261:2831-2832, 1989.
 61. Reidenberg, M.M.: Rejecting a double standard for scientific publication. Clin. Pharmacol. Ther., 46:598-599, 1989.
 62. Reidenberg, M.M.: The history of Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 47:277-279, 1990.
 63. Reidenberg, M.M.: The quality of clinical research. Clin. Pharmacol. Ther., 47:669-670, 1990.
 64. Reidenberg, M.M.: The state of drug development in the United States - 1990. A view from the academic community. Clin. Pharmacol. Ther., 48:1-9, 1990.
 65. Reidenberg, M.M.: Clinical Pharmacology. JAMA, (Contempo '91 issue), 265:3107-3109, 1991.

66. Reidenberg, M.M., Drayer, D.E.: Genetic regulation of drug metabolism and systemic lupus erythematosus in Lahita, R.G., editor: Systemic Lupus Erythematosus, second edition, Churchill-Livingston, New York, p. 885-892, 1992.
67. Meyer, B.R., Reidenberg, M.M.: Clinical pharmacology and aging, in Evans, J.G., Williams, T.F., editors: Oxford Textbook of Geriatric Medicine, Oxford Univ. Press, p. 105-116, 1992.
68. Reidenberg, M.M.: Effect of the Requirement for Triplicate Prescriptions for Benzodiazepines in New York State, Clin. Pharmacol. Ther. 1991; 50:129-131.
69. Reidenberg, J.W., Reidenberg, M.M.: Report of a survey of some aspects of editorial board peer review at Clinical Pharmacology and Therapeutics, Clin. Pharmacol. Ther., 1991; 50:1-3.
70. Reidenberg, M.M., Hodi, F.S.: A plea for prices in physician prescribing. JAMA, 1991; 266:3285.
71. Reidenberg, M.M.: Trends in Clinical Pharmacokinetics. Clinical Pharmacokinetics, 1993; 24:1-9.
72. Reidenberg, M.M.: Clinical pharmacology in the United States. Chinese J. Clin. Pharmacol., 1986; 2:205-209.
73. Reidenberg, M.M.: Renal drug elimination reevaluated. Chinese J. Clin. Pharmacol., 1986; 2:241-243.
74. Reidenberg, M.M.: The hospital formulary: A type of essential drug program. Chinese J. Clin. Pharmacol., 1993; 9:8-9.
75. Reidenberg, M.M.: Continuing medical education, an important part of a comprehensive essential drugs program. Chinese J. Clin. Pharmacol., 1993; 9:10-12.
76. Reidenberg, M.M.: Clinical Pharmacology. JAMA (Contempo '93 issue), 1993; 270:192-194.
77. Reidenberg, M.M.: Principles of drug dosing in renal failure. In Bennet, Wm., De Broe, M.E., Porter, G.A., Verpooten, G.A., eds: Clinical Nephrotoxins. Kluwer, Dordrecht,.
78. Reidenberg, M.M.: Chronic back pain (letter). World Health Forum, 1992; 14:61.
79. Dannenberg, A.J., Reidenberg, M.M.: Dietary fatty acids are also drugs. Clin. Pharmacol. Ther., 55:5-9, 1994.

80. Nierenberg, D.W., Reidenberg, M.M.: Criteria for judging proposals for national health care reform with respect to therapeutics. *Clin. Pharmacol. Ther.*, 55:1-4, 1994.
81. Reidenberg, M.M.: The Pinocchio factor. *Clin. Pharmacol. Ther.*, 55:247-248, 1994.
82. Reidenberg, M.M., Portenoy, R.K.: The need for an open mind about the treatment of chronic nonmalignant pain. *Clin. Pharmacol. Ther.*, 55:367-9, 1994.
83. Reidenberg, M.M.: Are Clinical Research Grant Applications Reviewed Fairly? *Clin. Pharmacol. Ther.*, 56:597-600, 1994.
84. Reidenberg, M.M.: Some smokers lie. *Clin. Pharmacol. Ther.*, 56:355, 1994.
85. Reidenberg, M.M.: Clinical Pharmacology. *JAMA (Contempo '95 issue)*, 273:1664-1665, 1995.
86. Reidenberg, M.M.: Review of book, *Problem Drugs*, *JAMA* 1995; 274:184-5.
87. Reidenberg, M.M., Editor: *Essential drugs and the WHO Model List: Addressing new issues*. *Clin. Pharmacol. Ther.*, 1996; 59:251-257.
88. Reidenberg, M.M.: The WHO Analgesic Ladder (ltr.) *JAMA*, 1996; 275:835.
89. Reidenberg, M.M.: Forward: Commentary on drug development, in Welling P.G., Lasagna L., Banakar U., eds. *The Drug Development Process: Increasing Efficiency and Cost Effectiveness*. Dekker, New York, in press.
90. Reidenberg, M.M.: Publication and proprietary information. *Clin. Pharmacol. Ther.*, 1996; 59:367-368.
91. Reidenberg, M.M.: Attitudes about clinical research. *The Lancet* 1996; 347:1188.
92. Reidenberg, M.M.: Barriers to controlling pain in patients with cancer. *The Lancet*, 1996; 347:1278.
93. Reidenberg, M.M.: Drug interactions with steroid hormones. *Tropical J. Obst. Gynec.*, 1994; 11 (suppl 1):34-35.
94. Scheidt, S., Reidenberg, M.M.. Generic warfarin: A difficult decision. *Cardiovascular Reviews and Reports*. 1998; (Feb) 46-48.
95. Reidenberg, M.M. Decreasing publication bias. *Clin. Pharmacol. Ther.*, 1998; 63:1-3.
96. Reidenberg, M.M., Breckenridge, A.: Drugs and the liver. *Clin. Pharmacol. Ther.*, 1998; 64:353-4, and *Br. J. Clin. Pharmacol.*, 1998;46:358-359.

97. Reidenberg, M.M.: Comment. *Clin. Pharmacol. Ther.*, 1998;46:465.
98. Reidenberg, M.M.: Therapeutics as a science, in van Boxtel CJ, Santoso B, Edwards IR, eds. *An International Textbook of Clinical Pharmacology*, John Wiley & Sons, Ltd., Chichester, England, in press.
99. Reidenberg, M.M.: Clinical pharmacology; the scientific basis of therapeutics. *Clin. Pharmacol. Ther.*, 1999;66:1-8. *The Pharmacologist*, 1999;41:100-105.
100. Reidenberg, M.M.: Environmental inhibition of 11-hydroxysteroid dehydrogenase. *Toxicology*, 2000;144:107-111.
101. Reidenberg, M.M.: Are We Treating Health or Physical Appearance When We Prescribe Drugs for Obesity? *Clin. Pharmacol. Ther.*, 2000;67:193-195.
102. Reidenberg, M.M.: Centers for Education and Research in Therapeutics. *Clin. Pharmacol. Ther.*, 2000;68:109-110.
103. Sajous, M-H, Reidenberg, MM.: Inhaled steroids and cromolyn OTC. Written testimony at FDA Hearing on over-the-counter drug products, June 28-9, 2000.
104. Reidenberg, M.M.: What is pharmacology? *Pharmacology International*, the IUPHAR Newsletter, #54, June 2000, p. 5.
105. Reidenberg, M.M.: Studies of gossypol in the treatment of cancer, in Coutinho EM, Spinola P, eds. *Reproductive Medicine: A Millennium Review*. Pearl River, NY, Parthenon 1999.
106. Reidenberg, M.M., Connor B. Counterfeit and Substandard Drugs. *Clin. Pharmacol. Ther.*, 2001; 69:189-193.
107. Reidenberg, MM. Releasing the grip of big pharma. *Lancet*, 2001; 358:664.
108. Reidenberg, MM: An open invitation for explanation about how drug prices are set. *Clin. Pharmacol. Ther.*, 2001; 70:205-7.
109. Reidenberg, MM, Reidenberg, JR: Who Should Have Access to the Research Data? *Clin. Pharmacol. Ther.*, 2002; 71:309-310.
110. Reidenberg MM. Sponsorship, authorship, and accountability (Ltr). *New Engl. J. Med.* 2002, 346:290-1.

111. Reidenberg MM. Thoughts from the Editor. *Clin. Pharmacol. Ther.* 2002; 71:1-2.
112. Reidenberg MM. Conflict of interest and medical publication. *Science and Engineering Ethics* 2002; 8:455-7.
113. Rajpal A, Reidenberg MM. Drug labeling should be kept current. *Clin. Pharmacol. Ther.*,2003; 73: 4-6.
114. Levy M, Reidenberg MM. What has been the impact of the concept of essential drugs? *Clin. Pharmacol. Ther.*, 2003; 73:275-8.
115. Jorens P, Verpooten GA, Reidenberg MM. Pharmacological aspects of nephrotoxicity. In: DeBroe MF, Porter GA, Bennett WM, Verpooten GA, eds. *Clinical Nephrotoxins: Renal Injury from Drugs and Chemical*. 2nd edition. Dordrecht, Kluwer Academic Publishers, 2003.
116. Reidenberg MM. Rational prescribing of essential medicines. (Ltr.) *Clin Pharm. Ther*, 2003; 74:195.
117. Reidenberg MM. Evolving ways drug therapy is individualized. *Clin Pharmacol Ther*, 2003; 74:197- 202.
118. Reidenberg MM. Evolving ways drug therapy is individualized. Letter response to Spector. *Clin Pharm Ther*, 2004; 76:97-8.
119. Reidenberg MM. Some thoughts about counterfeit and substandard drug products as a risk of drug importation; and: Lowering retail drug prices without importing cheaper drugs. Oral and written testimony to H.H.S. Task Force on Importation April 27, 2004 F.D.A. Docket No. 2004 N.0115. Drug
120. Reidenberg MM. Evaluation of scientific achievement. *J Investigative Med.* 2004;52;361-363.
121. Reidenberg MM. Lowering retail drug prices without importing cheaper drugs. *Annals Int Med.* 2004; E-letter: <http://www.annals.org/cgi/eletters/140/8/677>
122. Reidenberg MM, Walley T. The pros and cons of essential medicines for rich countries. *BMJ*, 2004; 329:1172.
123. Reidenberg MM. Pay for performance. *ACP Observer* 2005; Jan-Feb, P.3 (ltr).
124. Reidenberg MM. We should not say “drug safety” when we mean drug toxicity”. *WHO Pharmaceuticals Newsletter* 2006; No. 2, 7-8.

125. Reidenberg MM. Clinical trials report card. *N Engl J Med* 2006; 354:1428 (ltr).
126. Reidenberg MM. Informed consent or acknowledgment or disclosure. *Clin Pharmacol Ther* 2005; 78:439-440.
127. Reidenberg MM. Improving how we evaluate the toxicity of approved drugs. *Clin Pharmacol Ther* 2006; 80: 1-6.
128. Reidenberg MM, Jung BF. Comment about the three commentaries. *Pain Medicine* 2006; 7:365-6.
129. Reidenberg MM. World Health Organization program for the selection and use of Essential Medicines. *Clin Pharmacol Ther*, 2007; 81: 303-306.
130. Reidenberg MM. Are drugs for rare diseases “essential”? *Bull WHO* 2006; 84:686.
131. Jung B, Reidenberg MM. Physicians Being Deceived. *Pain Medicine* 2007; 8:433-7.
132. Reidenberg MM. Statins for primary prevention of coronary disease. *Lancet* (ltr), 2007; 369: 1078 in press
134. Atkinson AJ, Reidenberg MM. Effects of renal disease on pharmacokinetics, Chap. 5 in Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP, *Principles of Clinical Pharmacology*, 2nd edition, New York, Academic Press, 2007.
135. Reidenberg MM. World Health Organization program for the selection and use of essential medicines. *Clin Pharmacol Ther* 2007; 81: 603-6.
136. Jung B, Reidenberg MM. Physicians being deceived. *Pain Medicine*, 2007; 8:433-437.
137. Reidenberg MM. Benefit/risk ratio of statins in primary prevention. *Clin Pharmacol*, 2008; 83: 498-500.
138. Reidenberg MM. Time to abolish codeine. *ACP Observer* 2007; 27: 2 (ltr).
139. Reidenberg MM. Essential Medicines for the Whole World. *Clin Pharm Therapeutics* 2007; 82:500-503.
140. Reidenberg MM. A New Look at the Profession of Clinical Pharmacology. *Clin Pharm Ther*. 2008; 83: 213-217.
141. Reidenberg, M.M.: Therapeutics as a science, in van Boxtel CJ, Santoso B, Edwards IR,

eds. An International Textbook of Clinical Pharmacology, 2nd edition. John Wiley & Sons, Ltd., Chichester, England, 2008

142. Reidenberg MM. Can the Selection and Use of Essential Medicines Decrease Inappropriate Drug Use? *Clin Pharmacol Ther* 2010; 85: 581-583.
143. Reidenberg MM. Hunter Award Lecture. *Clin Pharm Ther* 2010; 87: 163-165.
144. Reidenberg MM. Essential Medicines for Everybody in the World; The World Health Organization Essential Medicines Program. In Finkel, M.L. (editor). *Perspectives in Public Health: Challenges for the 21st Century*. Westport, CT: Praeger Press, 2011
145. IUPHAR. *Clinical Pharmacology in Research, Teaching, and Health Care. Basic and Clinical Pharmacology and Toxicology* 2010; 107: 531-559.
146. . Reidenberg MM. Early Research on Renal Function and Drug Action. *Journal of Clinical Pharmacology*, 2012; 52: 7S-9S
147. Reidenberg MM. Drug discontinuation effects are part of the pharmacology of a drug. *JPET*, 2011; 339: 324-328.

Notes on Therapeutics

At: http://www.med.cornell.edu/cert/patients/notes_on_therapeutics.html

These Notes are commentaries created to provide patients, caregivers, and healthcare professionals with evidence-based information and opinions about important therapeutic issues. New notes are added periodically.

The Notes may be printed and distributed to patients and anyone else who may find them helpful.

[Preventing Some Serious Adverse Medication Events](#)

by Marcus M. Reidenberg, MD, FACP

[Whole Body Vibration Therapy for Osteoporosis](#)

by Marcus M. Reidenberg, MD, FACP

[The FDA and Drugs for Cancer](#)

by Marcus M. Reidenberg, MD, FACP

[The Controversy about Screening Mammography](#)

by Marcus M. Reidenberg, MD, FACP

[Benefits of Screening for Osteoporosis](#)

by Marcus M. Reidenberg, MD, FACP

[Melatonin and Sleep Disorders](#)

by Marcus M. Reidenberg, MD, FACP

[Adverse Effects of Suddenly Stopping a Medicine](#)

by Marcus M. Reidenberg, MD, FACP

[Safety of Metal on Metal Hip Implants](#)

by Marcus M. Reidenberg, MD, FACP

[Clopidogrel \(Plavix\) and Concurrent Proton Pump Inhibitors](#)

by Marcus M. Reidenberg, MD, FACP

[Calcium and vitamin D](#)

by Marcus M. Reidenberg, MD, FACP